| Labcorp

July 26, 2023

NASH/MASH: Present and Emerging Treatments

Nonalcoholic steatohepatitis (NASH/MASH) is the second leading cause of liver transplantation in the United States. Since available therapeutic options remain limited, developing new therapies that can change the disease outcomes for people living with NASH/MASH is vital. This brief article will look at the current NASH/MASH management options and discuss new drugs in development.

June 27, 2024

BEBPA EU Bioassays

September 25-27 in Prague, Czech Republic

Join us at BEBPA EU Bioassays 2024!

June 1, 2017

Targeting B Cell malignancies? Raji-Luc is a model to test CD19-directed CAR-T cells and other novel approaches

ALL is more commonly found in young children but also arises in older adults. Children have a >80% cure rate while adults only have a 20-30% cure rate. A similar disease is chronic lymphocytic leukemia (CLL) which is generally diagnosed in older adults. Both ALL and CLL have been identified as malignancies suitable for CD19-directed therapies.

August 1, 2020

A New Labcorp Offering: Predictive Oncology® Reconstructed Bone (r-Bone), plate-based, 3-dimensional (3D) culture assay that mimics the tumor microenvironment found in myeloma, acute myelogenous leukemia and solid tumor metastasis.

Growth of tumor cells within the bone marrow is a common phenomenon in hematologic malignancies.

July 1, 2021

Measuring human cytokines in mouse samples in the discovery setting: Understanding immunoassay technology and managing the risk

Introduction

At the protein level, humans and mice have similar, and at times nearly identical, amino acid sequences (Table 1).

Managing Your Health

Diseases & Therapeutic Areas

Treatment Modalities & Methods

Scientific Lab Disciplines

Labs

Industries